Phase 3 N=31 Lithium and Divalproex for the Treatment of Comorbid Rapid Cycling Bipolar Disorder and Substance Abuse Disorder
Bipolar Disorder
Primary: Time to Treatment for Emerging Symptoms of a Mood Relapse — 17.8; 15.9 weeks
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=108 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Acromegaly
Primary: Percentage of Patients With Relevant Reduction in Pituitary Tumour Volume (as Measured by MRI) From Baseline Volume (Visit 1) to Week 48 (After 12 Injections at Visit 5)…
Phase 3 N=150 Atrial Flutter Ablation With Contact Therapy Cool Path Ablation System Along With EnSite Velocity Contact System
Typical Atrial Flutter
Primary: Primary Safety:Incidence of Composite, Serious Adverse Events Within 7 Days Post Procedure — 3 participants
Phase 1 N=40 Immunogenicity and Safety of Live Attenuated Influenza Vaccine (Flumist) Administered by Nasal and Sublingual Route
Healthy
Primary: Passive Haemagglutination Inhibition Titer. — 380; 440 Titer
Phase 2 N=110 The Mechanisms of Manual Therapy in the Treatment of Low Back Pain
Low Back Pain
Primary: Believability of Placebo — 67; 37; 78 percentage of participants — p=<0.01
Phase 3 N=50 A Randomized Trial of Procrit vs. No Procrit in AML and High Risk MDS
Acute Myelogenous Leukemia · Myelodysplastic Syndrome · Leukemia
Primary: Median Number of Participant Transfusions Required During 12 Weeks of Treatment — 7; 7 Transfusions per Participant
N/A N=207 Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®
Glabellar Lines
Primary: Percentage of Participants Mostly or Very Satisfied With Their Glabellar Lines on the Facial Line Satisfaction Questionnaire (FLSQ) — 92.3 Percentage of participants
Phase 2 N=41 Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Breast Neoplasms
Primary: Objective Response (OR) — 4 Participants
Phase 3 N=1,083 Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
Endometrial Hyperplasia · Osteoporosis
Primary: Percentage of Participants With Hyperplasia at Screening
Phase 1 N=53 BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid Tumours
Neoplasms
Primary: Investigator Defined Dose Limiting Toxicity (DLT) During First Course of Treatment, Treated Set — 6; 2; 1; 6 participants
N/A N=431 A Multi-Center Study of Near-Infrared Spectroscopy (NIRS) for Hematoma Detection
TBI (Traumatic Brain Injury)
Primary: 1) Sensitivity of the Near-Infrared Spectroscopy (NIRS) Measurements for Identifying Intracranial Hematomas Due to Trauma. 2) Specificity of the Near-Infrared…
Phase 3 N=1,886 Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
Menopause · Osteoporosis
Primary: Percentage of Participants With Endometrial Hyperplasia at Month 12: Main Study — 0.30; 0.54; 0.00; 0.00 Percentage of Participants
Phase 2 N=129 A Randomized, Double-Blind, Comparator- and Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602 in Type 2 Diabetic Patients
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Fasting Plasma Glucose — 6.0; -0.5; -20.0; -16.0 mg/dL — p=0.4195
Phase 3 N=188 Clinical Evaluation of Therapy™ Cool Path™ Duo Cardiac Ablation System for the Treatment of Typical Atrial Flutter (AFL)
Typical Atrial Flutter
Primary: Primary Safety- Incidence of Intra Procedural Serious Cardiac Adverse Events Occuring Within 7 Days of Post-procedure, Regardless of Whether a Determination Can be Made…
Phase 3 N=309 Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry
Asthma
Primary: Mean Change From Baseline (BL) in Daily Evening (PM) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period — 39.1; 10.5 Liters/minute (L/min) — p=<0.001